ANTHEM — Anthem Biosciences Share Price
- IN₹528.00bn
- IN₹518.42bn
- IN₹21.24bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 63.98 | ||
| PEG Ratio (f) | 4.62 | ||
| EPS Growth (f) | 16.07% | ||
| Dividend Yield (f) | 0.28% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 16.09 | ||
| Price to Tang. Book | 16.1 | ||
| Price to Free Cashflow | 93.26 | ||
| Price to Sales | 25.8 | ||
| EV to EBITDA | 63.08 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 20.54% | ||
| Return on Equity | 20.35% | ||
| Operating Margin | 33.59% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 12,312.56 | 10,569.24 | 14,193.7 | 18,445.53 | 21,243.33 | 25,815.57 | 30,717.57 | 14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +49.45 | -16.85 | +8.99 | +22.83 | +33.57 | +27.97 | +10.48 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Anthem Biosciences Limited is an India-based contract research, development and manufacturing organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. The Company’s segments include CRDMO and Speciality Ingredients. The Company helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and others. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its CRDMO Services include Large Molecules, Small Molecules, HPAPI, Peptides, Lipids, ADCs and Oligonucleotides.
Directors
- Ganesh Sambasivam DRC (59)
- Satish Subbanna DRC (50)
- K Chandrappa COO (59)
- Ajay Bhardwaj CEO (65)
- Mohammed Gawir Baig CFO
- Shubha Kulkarni IND (58)
- Subramanian Madhavan IND (68)
- Ravikant Uppal IND (74)
- Ramesh Ramadurai IND (63)
- Divya Prasad CCO
- Last Annual
- March 31st, 2026
- Last Interim
- September 30th, 2026
- Incorporated
- June 13th, 2006
- Public Since
- July 21st, 2025
- No. of Employees
- 2,282
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India
- Shares in Issue
- 563,528,045

- Address
- No 49 F1 & F2 CANARA BANK ROAD, BANGALORE, 560099
- Web
- https://www.anthembio.com/
- Phone
- +91 8066724000
- Contact
- Divya Prasad
- Auditors
- K.P. Rao & Co.
Latest News for ANTHEM
Upcoming Events for ANTHEM
Anthem Biosciences Limited Corporate Analyst Meeting
Q3 2026 Anthem Biosciences Limited Earnings Release
Similar to ANTHEM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 09:17 UTC, shares in Anthem Biosciences are trading at IN₹936.95. This share price information is delayed by 15 minutes.
Shares in Anthem Biosciences last closed at IN₹936.95 and the price had moved by +34.16% over the past 365 days. In terms of relative price strength the Anthem Biosciences share price has outperformed the S&P BSE 100 Index by +36.57% over the past year.
The overall consensus recommendation for Anthem Biosciences is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Anthem Biosciences dividend yield is 0.21% based on the trailing twelve month period.
Last year, Anthem Biosciences paid a total dividend of IN₹2.00, and it currently has a trailing dividend yield of 0.21%. We do not have any data on when Anthem Biosciences is to next pay dividends.
We do not have data on when Anthem Biosciences is to next pay dividends. The historic dividend yield on Anthem Biosciences shares is currently 0.21%.
To buy shares in Anthem Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹936.95, shares in Anthem Biosciences had a market capitalisation of IN₹528.00bn.
Here are the trading details for Anthem Biosciences:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: ANTHEM
Based on an overall assessment of its quality, value and momentum Anthem Biosciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Anthem Biosciences is IN₹969.14. That is 3.44% above the last closing price of IN₹936.95.
Analysts covering Anthem Biosciences currently have a consensus Earnings Per Share (EPS) forecast of IN₹13.74 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anthem Biosciences. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +12.32%.
As of the last closing price of IN₹936.95, shares in Anthem Biosciences were trading +19.92% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Anthem Biosciences PE ratio based on its reported earnings over the past 12 months is 63.98. The shares last closed at IN₹936.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Anthem Biosciences' management team is headed by:
- Ganesh Sambasivam - DRC
- Satish Subbanna - DRC
- K Chandrappa - COO
- Ajay Bhardwaj - CEO
- Mohammed Gawir Baig - CFO
- Shubha Kulkarni - IND
- Subramanian Madhavan - IND
- Ravikant Uppal - IND
- Ramesh Ramadurai - IND
- Divya Prasad - CCO





